| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42f352cc5bd193c17ffff15bf60e16f7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0cfae1b5af044685c09687819cc61a7a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-244
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate |
1999-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13f43cf8f8046cca1119bdd229cba9cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_832ad8de20b95eef583e209aed53cfb2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_999be966e98111340806951999d49073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4fc33b072e9a49aa360daf844851761b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78155f875ba898257e09e8f23bd78400 |
| publicationDate |
2000-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1053751-A1 |
| titleOfInvention |
Compositions and methods for treating cell proliferation disorders |
| abstract |
Pharmaceutical compositions and methods are provided fornsuppressing tumor growth. The compositions comprise an IL-17 antagonistnand/or an IL-17 receptor antagonist and a pharmaceutically acceptable carrier.nThe compositions are administered in an amount effective to inhibit tumorncell proliferation. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8617552-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014023650-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8119131-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10344084-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7807155-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1984401-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9765140-B2 |
| priorityDate |
1999-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |